An Adaptive Phase 2/3 Open-Label Multicenter Study to Assess the Diagnostic Performance of Piflufolastat F 18 PET/CT and Its Impact on Intended Clinical Management in Patients with Suspected, or at High Risk for, Metastatic Clear Cell Renal Cell Carcinoma.

Description:

This is an adaptive Phase 2/3, open-label, multi-center, single-arm study designed to evaluate diagnostic performance of piflufolastat F 18 PET/CT in the staging of patients suspected of having, or who are at high risk for, metastatic ccRCC and its impact on intended clinical management.